News and Trends 5 Jul 2022
Brii Bio takes hepatitis B treatment option
Brii Biosciences Limited, based in China and the U.S., has exercised its option to acquire exclusive development and commercialization rights for VIR-3434 in Greater China as part of its broader collaboration with Vir Biotechnology, Inc. VIR-3434, also known as BRII-877, is a broadly neutralizing monoclonal antibody targeting hepatitis B virus (HBV) that is currently in […]
